Recombinant Human CCR3 Protein，His

CCR3, or C-C chemokine receptor type 3, is a member of the chemokine receptor family, primarily involved in the immune response and inflammation. It plays a crucial role in the migration of eosinophils, basophils, and T-helper type 2 (Th2) cells to sites of allergic inflammation and parasitic infections. The significance of CCR3 in various pathological conditions, such as asthma, allergic rhinitis, and autoimmune diseases, has prompted extensive research into its structure, function, and signaling mechanisms. Understanding the molecular interactions and pathways associated with CCR3 is essential for developing targeted therapies aimed at modulating its activity. Recombining CCR3 protein presents opportunities for studying its biological functions in vitro and in vivo, paving the way for potential therapeutic applications. By investigating CCR3’s surface interactions and ligand binding, researchers aim to identify small molecules or antibodies that can specifically inhibit its activity, offering new strategies for treating related diseases. Furthermore, CCR3 has emerged as a potential therapeutic target due to its involvement in mediating inflammatory responses, thereby contributing to the development of novel anti-inflammatory drugs. Given the rising prevalence of allergic disorders and inflammatory conditions, the study of CCR3 and its recombinant protein continues to be a significant area of biomedical research, promising insights into the modulation of immune responses and therapeutic interventions.